title: Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site 'A': effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN.
abstract: A novel murine monoclonal antibody against the fibrin alpha-chain N-terminus is presented, which reacts with desAA- and desAABB-fibrin. In immunoblot procedures, the antibody reacted with fibrin degradation products X and Y of non-crosslinked fibrin, and fragment E. No binding was observed to the fibrin fragment D-dimer, and fibrinogen fragments D and E. Minor binding to fibrinogen fragments X, and Y, and desBB-fibrin were presumably due to minor contamination with (desAA)-fibrin. A prerequisite for binding was release of fibrinopeptides A (FpA), the binding site being a fibrin-specific neo-epitope. No binding was observed to fibrinogen or to thrombin-treated dysfibrinogen MANNHEIM III (A alpha 16 Arg-->Cys) molecules, which do not release FpA. The antibody bound to abnormal fibrin molecules prepared from dysfibrinogen MANNHEIM I (A alpha 19 Arg-->Gly), albeit to a lesser extent than to normal fibrin. Binding of the antibody to the fibrin epitope was greatly enhanced by denaturation, e.g. by heat, or by treatment with chaotropic ions. Soluble fibrin in clinical samples is generally found as a complex with fibrinogen, since polymerization sites 'A' exposed by release of FpA react with complementary binding sites 'a' on the D-domains of other fibrin and fibrinogen molecules. Treatment of samples with NaSCN caused dissociation of fibrin monomer complexes. Reassociation was prevented by denaturation of both polymerization sites 'A' and 'a'. The antibody in combination with NaSCN-treatment of samples was useful for specific detection of fibrin monomer in plasma samples. Measurement was not influenced by fibrinogen degradation products, whereas fibrin degradation products at very high concentration caused some underestimation of fibrin monomer concentration.
authors.affiliation: University of Heidelberg, Klinikum Mannheim, I. Department of Medicine, Germany.
authors.forename: C E
authors.initials: CE
authors.lastname: Dempfle
authors.forename: M
authors.initials: M
authors.lastname: Dollman
authors.forename: H
authors.initials: H
authors.lastname: Lill
authors.forename: D
authors.initials: D
authors.lastname: Puzzovio
authors.forename: A
authors.initials: A
authors.lastname: Dessauer
authors.forename: D L
authors.initials: DL
authors.lastname: Heene
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D001666:Binding Sites, Antibody; D001667:Binding, Competitive; D005337:Fibrin / Q000032:analysis / Q000187:drug effects / Q000276:immunology; D005338:Fibrin Fibrinogen Degradation Products; D015241:Fibrinogens, Abnormal / Q000276:immunology*; D006801:Humans; D046911:Macromolecular Substances; D051379:Mice; D008807:Mice, Inbred BALB C; D010446:Peptide Fragments; D013861:Thiocyanates
chemical_list: D000911:Antibodies, Monoclonal; D005338:Fibrin Fibrinogen Degradation Products; D015241:Fibrinogens, Abnormal; D046911:Macromolecular Substances; D010446:Peptide Fragments; D013861:Thiocyanates; C024553:sodium thiocyanate; D005337:Fibrin